Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

This RCT (n=419) reports a median duration of progression-free survival which was statistically significantly longer with osimertinib than with platinum therapy plus pemetrexed (10.1 months vs. 4.4 months; HR 0.30; 95% CI 0.23 to 0.41; P<0.001).

Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitising and T790M resistance mutations in patients with non–small-cell lung cancer (NSCLC).

This study involved patients with T790M-positive advanced non–small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy.